Danaher Co. (NYSE:DHR) Stock Position Raised by Public Sector Pension Investment Board

Public Sector Pension Investment Board boosted its position in shares of Danaher Co. (NYSE:DHR) by 119.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,503 shares of the conglomerate’s stock after purchasing an additional 10,628 shares during the period. Public Sector Pension Investment Board’s holdings in Danaher were worth $4,873,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Harmony Asset Management LLC acquired a new position in Danaher during the second quarter valued at $301,000. Certified Advisory Corp increased its holdings in shares of Danaher by 4.5% in the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 40 shares during the period. DRW Securities LLC purchased a new stake in shares of Danaher in the second quarter worth approximately $385,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Danaher by 12.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the conglomerate’s stock worth $424,000 after purchasing an additional 165 shares during the period. Finally, Fairscale Capital LLC purchased a new position in Danaher during the second quarter valued at approximately $340,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of NYSE DHR opened at $276.93 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $205.12 billion, a P/E ratio of 46.94, a P/E/G ratio of 4.55 and a beta of 0.83. The business’s 50 day moving average is $268.95 and its two-hundred day moving average is $257.55.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm earned $2.05 EPS. The business’s revenue was down 2.9% on a year-over-year basis. On average, equities analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Evercore ISI lowered their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Stifel Nicolaus raised their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Robert W. Baird lifted their price target on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company started coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.